Picture of YARROW BIOSCIENCE logo

YARW — YARROW BIOSCIENCE News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapHigh Flyer

Vyne Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

* Vyne Therapeutics Inc  VYNE.OQ   VYNE.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 12
(estimated) for the period ending June 30 2024
    * The Bridgewater New Jersey-based  company is expected to
report
a 18.5% decrease in revenue to $110 thousand from $135 thousand
a year ago, according to the estimate from one analyst, based on
LSEG data.
    * ​LSEG's mean analyst estimate for Vyne Therapeutics Inc is
for a
loss of 19 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5.75​, above​ its last closing price of $1.77. ​​​

This summary was machine generated August 9 at 18:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on YARROW BIOSCIENCE

See all news